Eledon Pharmaceuticals Files 8-K with Corporate Updates

Ticker: ELDN · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1404281

Eledon Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEledon Pharmaceuticals, Inc. (ELDN)
Form Type8-K
Filed DateJun 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, filing-update

TL;DR

Eledon Pharma filed an 8-K detailing corporate changes and shareholder votes.

AI Summary

Eledon Pharmaceuticals, Inc. filed an 8-K on June 10, 2025, reporting on several key events. These include amendments to its articles of incorporation or bylaws, the submission of matters to a vote of security holders, and the filing of financial statements and exhibits. The company, formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Irvine, California.

Why It Matters

This filing indicates significant corporate actions and governance updates for Eledon Pharmaceuticals, potentially impacting its structure and shareholder engagement.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial distress or operational failures.

Key Players & Entities

  • Eledon Pharmaceuticals, Inc. (company) — Registrant
  • Novus Therapeutics, Inc. (company) — Former company name
  • Tokai Pharmaceuticals Inc (company) — Former company name
  • June 10, 2025 (date) — Date of earliest event reported

FAQ

What specific amendments were made to Eledon Pharmaceuticals' articles of incorporation or bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text.

What matters were submitted to a vote of security holders?

The filing confirms that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.

What financial statements and exhibits are being filed with this 8-K?

The filing states that financial statements and exhibits are included, but the specific content of these documents is not detailed in the provided text.

When was Eledon Pharmaceuticals, Inc. formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.?

The company was formerly known as Novus Therapeutics, Inc. with a name change date of 20170511, and formerly known as Tokai Pharmaceuticals Inc with a name change date of 20070622.

What is the business address of Eledon Pharmaceuticals, Inc.?

The business address is 19800 MacArthur Blvd., Suite 250, Irvine, California, 92612.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Eledon Pharmaceuticals, Inc. (ELDN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.